Tumor Suppression by Anti-Fibroblast Activation Protein Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts

• Published in: Cancers 2024-01, Vol.16 (2), p.449
• Main Authors: Glabman, Raisa A, Olkowski, Colleen P, Minor, Hannah A, Bassel, Laura L, Kedei, Noemi, Choyke, Peter L, Sato, Noriko
• Format: Article
• Language: English
• Subjects: Angiogenesis; Animal models; Antibodies; Bone growth; Bone marrow; Cancer; Cancer therapies; CD8 antigen; Cell activation; Chimeras; Clinical trials; Cloning; Ethylenediaminetetraacetic acid; Fibroblast activation protein; Fibroblasts; Flow cytometry; Growth factors; Head & neck cancer; I.R. radiation; Immunosuppressive agents; Lasers; Light; Metastases; Myeloid cells; Natural killer cells; Proteins; Scientific equipment and supplies industry; Stroma; Transgenic animals; Tumor microenvironment; Tumor suppression; Tumors; γ-Interferon
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16020449

Cancer-associated fibroblasts (CAFs) constitute a prominent cellular component of the tumor stroma, with various pro-tumorigenic roles. Numerous attempts to target fibroblast activation protein (FAP), a highly expressed marker in immunosuppressive CAFs, have failed to demonstrate anti-tumor efficacy in human clinical trials. Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor therapy that utilizes an antibody-photo-absorbing conjugate activated by near-infrared light. In this study, we examined the therapeutic efficacy of CAF depletion by NIR-PIT in two mouse tumor models. Using CAF-rich syngeneic lung and spontaneous mammary tumors, NIR-PIT against FAP or podoplanin was performed. Anti-FAP NIR-PIT effectively depleted FAP CAFs, as well as FAP myeloid cells, and suppressed tumor growth, whereas anti-podoplanin NIR-PIT was ineffective. Interferon-gamma production by CD8 T and natural killer cells was induced within hours after anti-FAP NIR-PIT. Additionally, lung metastases were reduced in the treated spontaneous mammary cancer model. Depletion of FAP stromal as well as FAP myeloid cells effectively suppressed tumor growth in bone marrow chimeras, suggesting that the depletion of both cell types in one treatment is an effective therapeutic approach. These findings highlight a promising therapy for selectively eliminating immunosuppressive FAP cells within the tumor microenvironment.